Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2009 - 2026)

Regeneron Pharmaceuticals has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $123.7 million in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 8.44% year-over-year to $123.7 million in Q2 2026; TTM through Jun 2026 was $528.6 million, a 3.63% increase from a year earlier, with the FY2025 full-year figure at $543.7 million, up 12.59% from the prior year.
• Depreciation & Amortization (CF) was $123.7 million for Q2 2026 at Regeneron Pharmaceuticals, roughly flat from $123.2 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $145.0 million in Q4 2025, with the low at $74.3 million in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $113.1 million, with a median of $117.4 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) jumped 38.58% in 2023, then fell 8.44% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $100.1 million in 2022, then gained by 12.89% to $113.0 million in 2023, then rose by 11.86% to $126.4 million in 2024, then rose by 14.72% to $145.0 million in 2025, then slipped by 14.69% to $123.7 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $123.7 million (Q2 2026), $123.2 million (Q1 2026), and $145.0 million (Q4 2025), per Business Quant data.